Variant Class–Specific Phenotypes and Outcomes in Pediatric TBX4‐Associated Pulmonary Hypertension
Pediatric Pulmonology · 2026
DOI: 10.1002/ppul.71857 ↗At a glance
Journal article in Pediatric Pulmonology, 2026. Written by Cara Morgan and 12 co-authors. Institution: UK National Paediatric Pulmonary Hypertension Service, Great Ormond Street Hospital for Children, London, UK. Major MEDLINE topics: T-Box Domain Proteins, Hypertension, Pulmonary. 40 references. The full text is freely available (open access, CC BY 4.0).
Abstract (original language)
Aim
To describe the variant class associations with phenotype, natural history, treatment response, and outcomes in children with TBX4 ‐associated pulmonary hypertension ( TBX4 ‐PH).
Methods
Retrospective cohort analysis of children < 18 years referred to the National Paediatric Pulmonary Hypertension Service between 2001 and 2025.
Results
Twenty‐one children were identified carrying either a copy number variant (CNV group = 10) encompassing TBX4 or a single nucleotide variant (SNV group = 11). Distinct phenotypic differences were observed between variant classes. Children in the CNV group were referred at a younger age ( p = 0.03), more frequently had prolonged oxygen dependence from birth ( p < 0.01), more severe lung disease ( p < 0.01) and cyanosis ( p = 0.04), congenital heart disease ( p = 0.03), neurodevelopmental disorders ( p < 0.01), and deafness ( p = 0.01). Children in the SNV group were less likely to have any lung disease ( p = 0.03). Histopathology from five children (CNV = 3, SNV = 2) demonstrated predominantly lung growth abnormalities with variable pulmonary vascular remodeling. Twenty of 21 (95%) children received long‐term pulmonary vasodilator therapy, and 9 (43%) received concurrent calcium‐channel blockers. Treatment‐naïve children ( n = 12) demonstrated stable/improved functional class with therapy initiation. Median follow‐up was 7.1 years (range 0.7–17.2). Transplant‐ or Potts shunt‐free survival at 1 and 5 years was 100% and 94.4% respectively and was worse in the CNV group (Log‐rank p < 0.05).
Conclusions
In this large pediatric TBX4 ‐PH cohort, children carrying CNVs had greater multisystem involvement and poorer outcomes than those carrying SNVs, highlighting the importance of the underlying genetic finding for risk stratification and tailored management strategies.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- UK National Paediatric Pulmonary Hypertension Service, Great Ormond Street Hospital for Children, London, UK.
- Department of Radiology, Great Ormond Street Hospital for Children, London, UK.
- St George's University Hospitals NHS Foundation Trust, SW Thames Centre for Genomic Medicine, London, UK.
- Department of Histopathology, Great Ormond Street Hospital for Children, London, UK.
- Department of Cardiology, Adult Congenital Heart Disease Unit, Queen Elizabeth Hospital Birmingham, Birmingham, UK.
- Institute of Cardiovascular Sciences, University of Birmingham, Birmingham, UK.
ORCID profiles: Cara Morgan, Andrew Constantine, Tomas Woodgate, Sadia Quyam, Shahin Moledina
Cite
APA
Morgan, C., Calder, A., Prapa, M., Sekar, T., Constantine, A., Woodgate, T., Barnes, A., McGovern, E., Aurora, P., Brugha, R., Quyam, S., Bush, A., & Moledina, S. (2026). Variant Class–Specific Phenotypes and Outcomes in Pediatric TBX4‐Associated Pulmonary Hypertension. Pediatric Pulmonology. https://doi.org/10.1002/ppul.71857
Vancouver
Morgan C, Calder A, Prapa M, Sekar T, Constantine A, Woodgate T, et al. Variant Class–Specific Phenotypes and Outcomes in Pediatric TBX4‐Associated Pulmonary Hypertension. Pediatric Pulmonology. 2026. doi:10.1002/ppul.71857
BibTeX
@article{Morgan2026,
author = {Morgan, Cara and Calder, Alistair and Prapa, Matina and Sekar, Thivya and Constantine, Andrew and Woodgate, Tomas and Barnes, Annabelle and McGovern, Eimear and Aurora, Paul and Brugha, Rossa and Quyam, Sadia and Bush, Andrew and Moledina, Shahin},
title = {Variant Class–Specific Phenotypes and Outcomes in Pediatric TBX4‐Associated Pulmonary Hypertension},
journal = {Pediatric Pulmonology},
year = {2026},
doi = {10.1002/ppul.71857}
}
EUVIMED